Claims for Patent: 8,287,888

Summary for Patent: 8,287,888

Title:	Thermosensitive polyphosphazene-bioactive molecule conjugates, preparation method thereof and use thereof
Abstract:	The present invention relates to a poly(organophosphazene)-bioactive molecule conjugates in which biodegradable and thermosensitive poly(organophosphazene) with a functional group showing the sol-gel phase transition with change of temperature is combined with various bioactive molecules, such as drugs, a preparation method thereof, and a use thereof for delivery of bioactive molecules.
Inventor(s):	Song; Soo-Chang (Namyangju, KR), Lee; Sun-Mi (Busan, KR), Kim; Chang-Won (Seoul, KR)
Assignee:	Korea Institute of Science and Technology (Seoul, KR)
Application Number:	11/568,852
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,287,888
Patent Claims:	1. A poly(organophosphazene)-bioactive molecule conjugate in which a biodegradable and thermosensitive poly(organophosphazene) with a functional group represented by the following Chemical Formula 1 and a bioactive molecule represented by the following substituent R.sup.10 are combined: ##STR00004## wherein, p is an integer between 7 and 50, R.sup.1 is selected from the group consisting of H, HCH.sub.2, CH.sub.3, CH.sub.2SH, CH(CH.sub.3).sub.2, CH.sub.2CH(CH.sub.3).sub.2, CH(CH.sub.3)C.sub.2H.sub.5, CH.sub.2CH.sub.2SCH.sub.3, CH.sub.2C.sub.6H.sub.5, CH.sub.2C.sub.6H.sub.4OH, CH.sub.2C.sub.2NH.sub.2C.sub.6H.sub.4, OCOC.sub.4N.sup.+H.sub.9, CO.sub.2C.sub.2H.sub.5, CH.sub.2CO.sub.2C.sub.2H.sub.5, (CH.sub.2).sub.2CO.sub.2C.sub.2H.sub.5, and HCONHCH(CH.sub.2C.sub.6H.sub.5), R.sup.2 is selected from the group consisting of CH.sub.3, C.sub.3H.sub.7, C.sub.4H.sub.9, C.sub.2H.sub.5, CH.sub.2C.sub.6H.sub.5, and CH.sub.2CHCH.sub.2, R.sup.3 is CH(W), R.sup.4 is selected from the group consisting of CO.sub.2, CO.sub.2CH.sub.2CO.sub.2, CO.sub.2CH(CH.sub.3)CO.sub.2, and CONHCH(X)CO.sub.2, R.sup.5 is selected from the group consisting of H, CH.sub.3, and C.sub.2H.sub.5, W and X are independently selected from the group consisting of H, HCH.sub.2, CH.sub.3, CH(CH.sub.3).sub.2, CH.sub.2CH(CH.sub.3).sub.2, CH(CH.sub.3)C.sub.2H.sub.5, CH.sub.2CH.sub.2SCH.sub.3, CH.sub.2C.sub.6H.sub.5, CH.sub.2C.sub.2NH.sub.2C.sub.6H.sub.4, OCOC.sub.4N.sup.+H.sub.9, CO.sub.2C.sub.2H.sub.5, (CH.sub.2).sub.2CO.sub.2C.sub.2H.sub.5, CH.sub.2OH, CH(CH.sub.3)OH, CH.sub.2C.sub.6H.sub.4OH, CH.sub.2COOH, CH.sub.2CH.sub.2COOH, CH.sub.2CONH.sub.2, C.sub.4H.sub.8NH.sub.2, C.sub.3H.sub.6NHC(.dbd.NH)NH.sub.2, CH.sub.2C.sub.3N.sub.2H.sub.3, and CH.sub.2SH, R.sup.6 is CH(Y), R.sup.7 is selected from the group consisting of C.sub.2H.sub.4, C.sub.3H.sub.6, C.sub.4H.sub.8, CH.sub.2C.sub.6H.sub.4, O, CONHCH(Z)O, CO, S, CONHCH(Z)S, N, CONHCH(Z)N, CON, COCHNH(Z)CON, and CONHCH(Z)CO, R.sup.8 is selected from the group consisting of OH, SH, H, CH.sub.3, C.sub.2H.sub.5, C.sub.3H.sub.7, C.sub.4H.sub.9, CH.sub.2C.sub.6H.sub.5, CH.sub.2CHCH.sub.2, and protecting groups as defined in Table 1 described in the detailed description of the present application, Y and Z are independently selected from the group consisting of H, HCH.sub.2, CH.sub.3, CH(CH.sub.3).sub.2, CH.sub.2CH(CH.sub.3).sub.2, CH(CH.sub.3)C.sub.2H.sub.5, CH.sub.2CH.sub.2SCH.sub.3, CH.sub.2C.sub.6H.sub.5, CH.sub.2C.sub.2NH.sub.2C.sub.6H.sub.4, OCOC.sub.4N.sup.+H.sub.9, CH.sub.2OH, CH(CH.sub.3)OH, CH.sub.2C.sub.6H.sub.4OH, CH.sub.2COOH, CH.sub.2CH.sub.2COOH, CH.sub.2CONH.sub.2, C.sub.4H.sub.8NH.sub.2, C.sub.3H.sub.6NHC(.dbd.NH)NH.sub.2, CH.sub.2C.sub.3N.sub.2H.sub.3, and CH.sub.2SH, R.sup.9 is selected from the group consisting of OH, SH, H, NH.sub.2, CH.sub.3, C.sub.2H.sub.5, C.sub.3H.sub.7, C.sub.4H.sub.9, CH.sub.2C.sub.6H.sub.5, CH.sub.2CHCH.sub.2, NHCH(SH)CO.sub.2H, NH(CH.sub.2).sub.qSH, NH(CH.sub.2CH.sub.2NH).sub.rH, [NHCH(C.sub.4H.sub.8NH.sub.2)CO].sub.rOH, [NHCH[(CH.sub.2).sub.3C(.dbd.NH)(NH.sub.2)]CO].sub.rOH, and protamines, q is an integer between 1 and 20, r is an integer between 1 and 18000, R.sup.10 is selected from the group consisting of paclitaxel, doxorubicin, camptothecin, epirubicine, 5-fluorouracil, 10-hydroxycamptothecin, 10-aminocamptothecin, 7-ethylcamptothecin, irinotecan, methotrexate, mitomycin C, taxoid, docetaxel, chlorambucil, calicheamicin, maytansinoid, 2-pyrrolino-doxorubicin (AN-201), daunorubicin, butyric acid, melphalan, 4'-dimethyldeoxypodophyllotoxin, curcumin, podophyllotoxin, epipodophyllotoxin, 4-.beta.-amino-4'-O-demethylepipodophyllotoxin, tallysomycin S10b, daunomycin, duocarmycin A, duocarmycin SA, cis-aconityl-daunomycin, calicheamicin, diazeniumdiolate, netropsin, 6-metcaptopurine, glucuronidation, phosmidosine, streptonigrin, hematoporphyrin, desferrioxamine (DFO), deferiprone, acivicin, estramustine, enediyne, arginine-glycin-aspatic acid peptide, neuropeptides, albumin, Bovin serum albumin (BSA), bovin pancreatic ribonuclease (RNase A), Bovin seminal ribonuclease (BS-RNase), Bowman-birk protease inhibitor (BBI), collagen, fibronetin, laminin, erythropoietin (EPO), interferon, hirudin, colony stimulating factor (CSF), insulin, desmopressin, glucagon-like peptide 1(GLP1), human growth hormone antagonist, tumor necrosis factor receptor 1(TNFR1), asparaginase, adenosine deaminase, transforming growth factor-beta(TGF-beta), bone morphogenetic proteins (BMPs), growth factors, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), cytokines, theanine dexamethason, heparin, chitosan, hyaluronan, cyclodextran, starch, carbohydrate, saccharide, fluorescent protein (such as green fluorescent protein(GFP), red fluorescent protein (RFP)), virus-like particle (VLP), and vaccine, a, b, c, d, e, and f respectively represent the content of each substituent, wherein a, b, d, and f are independently from 0.01 to 1.9, c and e are independently from 0 to 1.9, and a+b+c+d+e+f=2.0, and n is from 5 to 100000. 2. The poly(organophosphazene)-bioactive molecule conjugate according to claim 1, selected from the group consisting of poly[(isoleucineethylester)(aminomethoxypolyethyleneglycol 550)(glycylglycine)(glycylglycylpaclitaxel)phosphazene], poly[(isoleucineethylester)(aminomethoxypolyethyleneglycol 550)(glycylglycine)(glycylglycyldoxorubicin)phosphazene], poly[(isoleucineethylester)(aminomethoxypolyethyleneglycol 550)(glycylglycine)(glycylglycylglycin-arginine-glycin-asparagine-cerinic- acidpeptied)phosphazene], poly[(isoleucineethylester)(aminomethoxypolyethyleneglycol 550)(glycylglycine)(glycylglycylglycin-ethyl-ester) (glycylglycylglycin-arginine-glycin-asparagine-cerinicacidpeptied)phospha- zene], and poly[(isoleucineethylester)(aminomethoxypolyethyleneglycol 550)(glycylglycine)(glycylglycylglycin-arginine-glycin-asparagine-tyrosin- icacidpeptied)phosphazene]. 3. A preparation method of the poly(organophosphazene)-bioactive molecule conjugate according to claim 1 comprising the steps of: (1) thermopolymerizing a phosphazene trimer represented by the following Chemical Formula 2, to prepare a linear polymer of dichloro phosphazene represented by the following Chemical Formula 3 ##STR00005## (wherein n is an integer between 7 and 100,000); (2) reacting the compound prepared in step (1) of Chemical Formula 3 with 0.01 to 1.9 equivalents of an amino acid ester represented by the following Chemical Formula 4 or a salt thereof NH.sub.2CH(R.sup.1)CO.sub.2R.sup.2; [Chemical Formula 4] (3) reacting the compound prepared in step (2) with 0 to 1.9 equivalents of one selected from amino acid, peptide, and depsipeptide ester, represented by the following Chemical Formula 5, and a salt thereof NH.sub.2(R.sup.3)(R.sup.4)(R.sup.5); [Chemical Formula 5] (4) reacting the compound prepared in step (3) with 0.01 to 1.9 equivalents of substituents with a functional group represented by the following Chemical Formula 6, or a salt thereof NH.sub.2(R.sup.6)(R.sup.7)(R.sup.8); [Chemical Formula 6] (5) reacting the compound prepared in step (4) with 0.01 to 1.9 equivalents of aminomethoxy polyethylene glycol represented by the following Chemical Formula 7, or a salt thereof NH.sub.2(CH.sub.2CH.sub.2O).sub.pCH.sub.3; and [Chemical Formula 7] (6) reacting the compound prepared in step (5) with a bioactive molecule selected from the group consisting of proteins, polypeptides, peptides, vaccines, genes, hormones, anti-cancer drugs, and angiogenesis inhibitors wherein, p is an integer between 7 and 50; R.sup.1 is selected from the group consisting of H, HCH.sub.2, CH.sub.3, C.sub.2SH, CH(CH.sub.3).sub.2, CH.sub.2CH(CH.sub.3).sub.2, CH(CH.sub.3)C.sub.2H.sub.5, CH.sub.2CH.sub.2SCH.sub.3, CH.sub.2C.sub.6H.sub.5, CH.sub.2C.sub.6H.sub.4OH, CH.sub.2C.sub.2NH.sub.2C.sub.6H.sub.4, OCOC.sub.4N.sup.+H.sub.9, CO.sub.2C.sub.2H.sub.5, CH.sub.2CO.sub.2C.sub.2H.sub.5, (CH.sub.2).sub.2CO.sub.2C.sub.2H.sub.5, and HCONHCH(CH.sub.2C.sub.6H.sub.5), and R.sup.2is selected from the group consisting of CH.sub.3, C.sub.3H.sub.7, C.sub.4H.sub.9, C.sub.2H.sub.5, CH.sub.2C.sub.6H.sub.5, and CH.sub.2CHCH.sub.2; R.sup.3 is CH(W), R.sup.4 is selected from the group consisting of CO.sub.2, CO.sub.2CH.sub.2CO.sub.2, CO.sub.2CH(CH.sub.3)CO.sub.2, and CONHCH(X)CO.sub.2, R.sup.5 is selected from the group consisting of H, CH.sub.3, and C.sub.2H.sub.5, W and X are independently selected from the group consisting of H, HCH.sub.2, CH.sub.3, CH(CH.sub.3).sub.2, CH.sub.2CH(CH.sub.3).sub.2, CH(CH.sub.3)C.sub.2H.sub.5, CH.sub.2CH.sub.2SCH.sub.3, CH.sub.2C.sub.6H.sub.5, CH.sub.2C.sub.2NH.sub.2C.sub.6H.sub.4, OCOC.sub.4N.sup.+H.sub.9, CO.sub.2C.sub.2H.sub.5, (CH.sub.2).sub.2CO.sub.2C.sub.2H.sub.5, CH.sub.2OH, CH(CH.sub.3)OH, CH.sub.2C.sub.6H.sub.4OH, CH.sub.2COOH, CH.sub.2CH.sub.2COOH, CH.sub.2CONH.sub.2, C.sub.4H.sub.8NH.sub.2, C.sub.3H.sub.6NHC(.dbd.NH)NH.sub.2, CH.sub.2C.sub.3N.sub.2.sub.3, and C.sub.2SH, R.sup.6 is CH(Y), R.sup.7 is selected from the group consisting of C.sub.2H.sub.4, C.sub.3H.sub.6, C.sub.4H.sub.8, CH.sub.2C.sub.6H.sub.4, CH.sub.2CO.sub.2, O, CONHCH(Z)O, CO, CO.sub.2, S, CONHCH(Z)S, N, CONHCH(Z)N, CON, COCHNH(Z)CON, CONHCH(Z)CO, and CONHCH(Z)CO.sub.2, R.sup.8 is selected from the group consisting of OH, SH, H, CH.sub.3, C.sub.2H.sub.5, C.sub.3H.sub.7, C.sub.4H.sub.9, CH.sub.2C.sub.6H.sub.5, CH.sub.2CHCH.sub.2, and protecting groups as defined in Table 1 described in the detailed description of the present invention, Y and Z are independently selected from the group consisting of H, HCH.sub.2, CH.sub.3, CH(CH.sub.3).sub.2, CH.sub.2CH(CH.sub.3).sub.2, CH(CH.sub.3)C.sub.2H.sub.5, CH.sub.2CH.sub.2SCH.sub.3, CH.sub.2C.sub.6H.sub.5, CH.sub.2C.sub.2H.sub.2C.sub.6H.sub.4, OCOC.sub.4N.sup.+H.sub.9, CO.sub.2C.sub.2H.sub.5, (CH.sub.2).sub.2CO.sub.2C.sub.2H.sub.5, CH.sub.2OH, CH(CH.sub.3)OH, CH.sub.2C.sub.6H .sub.4OH, CH.sub.2COOH, CH.sub.2CH.sub.2COOH, CH.sub.2CONH.sub.2, C.sub.4H.sub.8NH.sub.2, C.sub.3H.sub.6NHC(.dbd.NH)NH.sub.2, CH.sub.2C.sub.3N.sub.2H.sub.3, and CH.sub.2SH, R.sup.9 is selected from the group consisting of OH, SH, H, NH.sub.2, CH.sub.3, C.sub.2H.sub.5, C.sub.3H.sub.7, C.sub.4H.sub.9, CH.sub.2C.sub.6H.sub.5, CH.sub.2CHCH.sub.2, NHCH(SH)CO.sub.2H, NH(CH.sub.2).sub.qSH, NH(CH.sub.2CH.sub.2NH).sub.rH, [NHCH(C.sub.4H.sub.8NH.sub.2)CO].sub.rOH, [NHCH[(CH.sub.2).sub.3C(.dbd.NH)(NH.sub.2)]CO].sub.rOH, and protamines, q is an integer between 1 and 20, r is an integer between 1 and 18000; R.sup.10 is selected from the group consisting of paclitaxel, doxorubicin, camptothecin, epirubicine, 5-fluorouracil, 10-hydroxycamptothecin, 10-aminocamptothecin, 7-ethylcamptothecin, irinotecan, methotrexate, mitomycin C, taxoid, docetaxel, chlorambucil, calicheamicin, maytansinoid, 2-pyrrolino-doxorubicin (AN-201), daunorubicin, butyric acid, melphalan, 4'-dimethyldeoxypodophyllotoxin, curcumin, podophyllotoxin, epipodophyllotoxin, 4-.beta.-amino-4'-O-demethylepipodophyllotoxin, tallysomycin S10b, daunomycin, duocarmycin A, duocarmycin SA, cis-aconityl-daunomycin, calicheamicin, diazeniumdiolate, netropsin, 6-metcaptopurine, glucuronidation, phosmidosine, streptonigrin, hematoporphyrin, desferrioxamine (DFO), deferiprone, acivicin, estramustine, enediyne, arginine-glycin-aspatic acid peptide, neuropeptides, albumin, Bovin serum albumin (BSA), bovin pancreatic ribonuclease (RNase A), Bovin seminal ribonuclease (BS-RNase), Bowman-birk protease inhibitor (BBI), collagen, fibronetin, laminin, erythropoietin (EPO), interferon, hirudin, colony stimulating factor (CSF), insulin, desmopressin, glucagon-like peptide 1(GLP1), human growth hormone antagonist, tumor necrosis factor receptor 1(TNFR1), asparaginase, adenosine deaminase, transforming growth factor-beta (TGF-beta), bone morphogenetic proteins (BMPs), growth factors, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), cytokines, theanine, dexamethasone, heparin, chitosan, hyaluronan, cyclodextran, starch, carbohydrate, saccharide, fluorescent proteins, virus-like particle (VLP), and vaccine, a, b, c, d, e, and f respectively represent the content of each substituent, wherein a, b, and f are independently from 0.01 to 1.9, c, d, and e are independently from 0 to 1.9, and a+b+c+d+e+f=2.0, and n is from 5 to 100000. 4. The method according to claim 3, between said step (5) and step (6), further comprising a step (5-1) of dehydrogenating or de-allylesterificating the product of said step (5), when the product of said step (5) contains R.sup.8 in Chemical Formula 6 selected from the group consisting of CH.sub.2C.sub.6H.sub.5 and CH.sub.2CHCH.sub.2. 5. The method according to claim 3, between said step (5) and step (6), further comprising a step (5-2) of reacting the product of said step (5) with one or more selected from lysine, arginine, cystein, thiol alkylamine, polyethyleneimine, polylysine, polyarginine, and protamine. 6. A poly(organophosphazene) hydrogel containing poly(organophosphazene)-bioactive molecule conjugate of the following Chemical Formula 1 showing sol-gel phase transition with change of temperature: ##STR00006## wherein, p is an integer between 7 and 50, R.sup.1 is selected from the group consisting of H, HCH.sub.2, CH.sub.3, CH.sub.2SH, CH(CH.sub.3).sub.2, CH(CH.sub.3).sub.2, CH(CH.sub.3)C.sub.2H.sub.5, CH.sub.2CH.sub.2SCH.sub.3, CH.sub.2C.sub.6H.sub.5, CH.sub.2C.sub.6H.sub.4OH, CH.sub.2C.sub.2NH.sub.2C.sub.6H.sub.4, OCOC.sub.4N.sup.+H.sub.9, CO.sub.2C.sub.2H.sub.5, CH.sub.2CO.sub.2C.sub.2H.sub.5, (CH.sub.2).sub.2CO.sub.2C.sub.2H.sub.5, and HCONHCH(CH.sub.2C.sub.6H.sub.5), R.sup.2 is selected from the group consisting of CH.sub.3, C.sub.3H.sub.7, C.sub.4H.sub.9, C.sub.2H.sub.5, CH.sub.2C.sub.6H.sub.5, and CH.sub.2CHCH.sub.2, R.sup.3 is CH(W), R.sup.4 is selected from the group consisting of CO.sub.2, CO.sub.2CH.sub.2CO.sub.2, CO.sub.2CH(CH.sub.3)CO.sub.2, and CONHCH(X)CO.sub.2, R.sup.5 is selected from the group consisting of H, CH.sub.3, and C.sub.2H.sub.5, W and X are independently selected from the group consisting of H, HCH.sub.2, CH.sub.3, CH(CH.sub.3).sub.2, CH(CH.sub.3).sub.2, CH(CH.sub.3)C.sub.2H.sub.5, CH.sub.2CH.sub.2SCH.sub.3, CH.sub.2C.sub.6H.sub.5, CH.sub.2C.sub.2NH.sub.2C.sub.6H.sub.4, OCOC.sub.4N.sup.+H.sub.9, CO.sub.2C.sub.2H.sub.5, (CH.sub.2).sub.2CO.sub.2C.sub.2H.sub.5, CH.sub.2OH, CH(CH.sub.3)OH, CH.sub.2C.sub.6H.sub.4OH, CH.sub.2COOH, CH.sub.2CH.sub.2COOH, CH.sub.2CONH.sub.2, C.sub.4H.sub.8NH.sub.2, C.sub.3H.sub.6NHC(.dbd.NH)NH.sub.2, CH.sub.2C.sub.3N.sub.2H.sub.3, and CH.sub.2SH, R.sup.6 is CH(Y), R.sup.7 is selected from the group consisting of C.sub.2H.sub.4, C.sub.3H.sub.6, C.sub.4H.sub.8, CH.sub.2C.sub.6H.sub.4, O, CONHCH(Z)O, CO, S, CONHCH(Z)S, N, CONHCH(Z)N, CON, COCHNH(Z)CON, and CONHCH(Z)CO, R.sup.8 is selected from the group consisting of OH, SH, H, CH.sub.3, C.sub.2H.sub.5, C.sub.3H.sub.7, C.sub.4H.sub.9, CH.sub.2C.sub.6H.sub.5, CH.sub.2CHCH.sub.2, and protecting groups as defined in Table 1 described in the detailed description of the present application, Y and Z are independently selected from the group consisting of H, HCH.sub.2, CH.sub.3, CH(CH.sub.3).sub.2, CH.sub.2CH(CH.sub.3).sub.2, CH(CH.sub.3)C.sub.2H.sub.5, CH.sub.2CH.sub.2SCH.sub.3, CH.sub.2C.sub.6H.sub.5, CH.sub.2C.sub.2H.sub.2C.sub.6H.sub.4, OCOC.sub.4N.sup.+H.sub.9, CH.sub.2OH, CH(CH.sub.3)OH, CH.sub.2C.sub.6H.sub.4OH, CH.sub.2COOH, CH.sub.2CH.sub.2COOH, CH.sub.2CONH.sub.2, C.sub.4H.sub.8NH.sub.2, C.sub.3H.sub.6NHC(.dbd.NH)NH.sub.2, CH.sub.2C.sub.3N.sub.2H.sub.3, and CH.sub.2SH, R.sup.9 is selected from the group consisting of OH, SH, H, NH.sub.2, CH.sub.3, C.sub.2H.sub.5, C.sub.3H.sub.7, C.sub.4H.sub.9, CH.sub.2C.sub.6H.sub.5, CH.sub.2CHCH.sub.2, NHCH(SH)CO.sub.2H, NH(CH.sub.2).sub.qSH, NH(CH.sub.2CH.sub.2NH).sub.rH, [NHCH(C.sub.4H.sub.8NH.sub.2)CO].sub.rOH, [NHCH[(CH.sub.2).sub.3C(.dbd.NH)(NH.sub.2)]CO].sub.rOH, and protamines, q is an integer between 1 and 20, r is an integer between 1 and 18000, R.sup.10 is selected from the group consisting of paclitaxel, doxorubicin, camptothecin, epirubicine, 5-fluorouracil, 10-hydroxycamptothecin, 10-aminocamptothecin, 7-ethylcamptothecin, irinotecan, methotrexate, mitomycin C, taxoid, docetaxel, chlorambucil, calicheamicin, maytansinoid, 2-pyrrolino-doxorubicin (AN-201), daunorubicin, butyric acid, melphalan, 4'-dimethyldeoxypodophyllotoxin, curcumin, podophyllotoxin, epipodophyllotoxin, 4-.beta.-amino-4'-O-demethylepipodophyllotoxin, tallysomycin S10b, daunomycin, duocarmycin A, duocarmycin SA, cis-aconityl-daunomycin, calicheamicin, diazeniumdiolate, netropsin, 6-metcaptopurine, glucuronidation, phosmidosine, streptonigrin, hematoporphyrin, desferrioxamine (DFO), deferiprone, acivicin, estramustine, enediyne, arginine-glycin-aspatic acid peptide, neuropeptides, albumin, Bovin serum albumin (BSA), bovin pancreatic ribonuclease (RNase A), Bovin seminal ribonuclease(BS-RNase), Bowman-birk protease inhibitor (BBI), collagen, fibronetin, laminin, erythropoietin (EPO), interferon, hirudin, colony stimulating factor (CSF), insulin, desmopressin, glucagon-like peptide 1(GLP1), human growth hormone antagonist, tumor necrosis factor receptor 1(TNFR1), asparaginase, adenosine deaminase, transforming growth factor-beta(TGF-beta), bone morphogenetic proteins (BMPs), growth factors, tumor necrosis factor-related apoptosis-inducing ligand(TRAIL), cytokines, theanine, dexamethasone, heparin, chitosan, hyaluronan, cyclodextran, starch, carbohydrate, saccharide, fluorescent proteins, virus-like particle(VLP), and vaccine, a, b, c, d, e, and f respectively represent the content of each substituent, wherein a, b, d, and f are independently from 0.01 to 1.9, c and e are independently from 0 to 1.9, and a+b+c+d+e+f=2.0, and n is from 5 to 100000. 7. The hydrogel according to claim 6, wherein the poly(organophosphazene)-bioactive molecule conjugate is dissolved in one or more selected from the group consisting of water, buffer solution, acid solution, basic solution, salt solution, saline solution, water for injection, and glucose salt solution, and the concentration of the poly(organophosphazene))-bioactive molecule conjugate is from 1 to 50 wt. %. 8. A bioactive molecule delivery composition, containing one or more poly(organophosphazene)-bioactive molecule conjugates according to claim 1. 9. The bioactive molecule delivery composition according to claim 8, further comprising one or more selected from the group consisting of additional bioactive molecules, cells and additives. 10. The bioactive molecule delivery composition according to claim 9, wherein the content of the additive is 1.times.10.sup.-6 to 30 wt % based on the total weight of the composition, and the additive is selected from the group consisting of cationic polymers having the molecular weight from 200 to 750,000, poly(N-vinyl-2-pyrrolidone), polyvinylacetate (PVA), hyaluronic acid, chondroitin sulfate, heparin, alginate, amiloride, procainamide, acetyl-beta-methylcholine, spermine, spermidine, lysozyme, fibroin, albumin, collagen, growth factors, bone morphogenetic proteins (BMPs), dexamethasone, fibronectin, fibrinogen, thrombin, proteins, cremophor EL, dexrazoxane, leucovorin, ricinoleic acid, phospholipid, small intestinal submucosa, vitamin E, polyglycerol ester of fatty acid, Labrafil, Labrafil M1944CS, citric acid, glutamic acid, hydroxypropyl methylcellulose, gelatin, isopropyl myristate, Eudragit, tego betain, dimyristoylphosphatidylcholine, scleroglucan, ethanol, dimethyl sulfoxide, preservatives, sugars, polyols, sugar-containing polyols, amino acids, polymer-containing polyols, sugar-containing amino acids, surfactants, sugar-containing ions, silicate, NaCl, KCl, NaBr, Nal, LiCl, n-Bu.sub.4NBr, n-Pr.sub.4NBr, Et.sub.4NBr, Mg(OH).sub.2, Ca(OH).sub.2, ZnCO.sub.3, Ca.sub.3(PO.sub.4).sub.2, ZnCl.sub.2, (C.sub.2H3O.sub.2).sub.2Zn, ZnCO.sub.3, CdCl.sub.2, HgCl.sub.2, CoCl.sub.2, (CaNO.sub.3).sub.2, BaCl.sub.2, MgCl.sub.2, PbCl.sub.2, AlCl.sub.3, FeCl.sub.2, FeCl.sub.3, NiCl.sub.2, AgCl, AuCl.sub.3, CuCl.sub.2, sodium tetradecyl sulfate, dodecyltrimethylammonium bromide, dodecyltrmethylammoniurn chloride, and tetradecyltrimethylammonium bromide. 11. The bioactive molecule delivery composition according to claim 9, wherein the additional bioactive molecule is selected from the group consisting of proteins, polypeptides, peptides, vaccines, genes, hormones, anti-cancer drugs, and angiogenesis inhibitors and the content of the additional bioactive molecule is from 1.times.10.sup.-8 to 50 vol % based on the total volume of the composition. 12. The bioactive molecule delivery composition according to claim 11, wherein the protein, polypeptide, or peptide is one or more selected from the group consisting of erythropoietin (EPO), interferon-alpha, interferon-beta, interferon-gamma, growth hormone, growth hormone releasing factor, nerve growth factor (NGF), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), macrophage-colony stimulating factor (M-CSF), blood clotting factor, insulin, oxytocin, vasopressin, adrenocorticotropic hormone, epidermal growth factor, platelet-derived growth factor (PDGF), prolactin, luliberin, luteinizing hormone releasing hormone (LHRH), LHRH agonists, LHRH antagonists, somatostatin, glucagon, interleukin-2(IL-2), interleukin-11(IL-11), gastrin, tetragastrin, pentagastrin, urogastrone, secretin, calcitonin, enkephalins, endorphins, angiotensins, thyrotropin releasing hormone(TRH), tumor necrosis factor (TNF), tumor necrosis factor related apoptosis inducing ligand (TRAIL), heparinase, bone morphogenic protein (BMP), human atrial natriuretic peptide (hANP), glucagon-like peptide (GLP-1), renin, bradykinin, bacitracins, polymyxins, colistins, tyrocidine, gramicidins, cyclosporins and synthetic analogs thereof, monoclonal antibody, antibody, ferment, and cytokines; the vaccine is hepatitis vaccine; the gene is one or more selected from the group consisting of small interference RNA (siRNA), plasmid DNA, and antisense oligodeoxynucleotide (AS-ODN); the hormone is one or more selected from the group consisting of testosterone, estradiol, progesterone, prostaglandins and synthetic analogs thereof; the anti-cancer drug is one or more selected from the group consisting of paclitaxel, doxorubicin, 5-fluorouracil, cisplatin, carboplatin, oxaliplatin, tegafur, irinotecan, docetaxel, cyclophosphamide, cemcitabine, ifosfamide, mitomycin C, vincristine, etoposide, methotrexate, topotecan, tamoxifen, vinorelbine, camptothecin, danuorubicin, chlorambucil, bryostatin-1, calicheamicin, mayatansine, levamisole, DNA recombinant interferon alfa-2a, mitoxantrone, nimustine, interferon alfa-2a, doxifluridine, formestane, leuprolide acetate, megestrol acetate, carmofur, teniposide, bleomycin, carmustine, heptaplatin, exemestane, anastrozole, estramustine, capecitabine, goserelin acetate, polysaccharide potassium, medroxypogesterone acetate, epirubicin, letrozole, pirarubicin, topotecan, altretamine, toremifene citrate, BCNU, taxotere, actinomycin D, polyethylene glycol conjugated protein, and synthetic analogs thereof; and the angiogenesis inhibitor is one or more selected from the group consisting of BMS-275291, Clodronate, 6-deoxy-6-demethyl-4-dedimethylaminotetracycline, Doxycycline, Marimastat, 2-Methoxyestradiol, Squalamine, SU5164, Thalidomide, TNP-470, Combretastatin A4, Soy Isoflavone, Enzastaurin, CC 5013, Celecoxib, ZD 6474, Halofuginone hydrobromide, interferon-alpha, Bevacizumab, AE-941, Interleukin-12, VEFG-trap, Cetuximab, and synthetic analogs thereof. 13. The bioactive molecule delivery composition according to claim 9, wherein the cell is one or more selected from the group consisting of preosteoblast, chondrocyte, umbilical vein endothelial cell (UVEC), osteoblast, adult stem cell, schwann cell, oligodendrocyte, hepatocyte, mural cell (used in combination with UVEC), myoblast, insulin-secreting cell, endothelial cell, smooth muscle cell, fibroblast, .beta.-cell, endodermal cell, hepatic stem cell, juxraglomerular cell, skeletal muscle cell, keratinocyte, melanocyte, langerhans cell, merkel cell, dermal fibroblast, and preadipocyte. 14. The bioactive molecule delivery composition according to claim 8, which is administered through an administration route selected from the group consisting of administration to outward intestinal tract, opthalmologically administration, injection into the cartilage tissue, bone tissue, fat tissue or cancer tissue, suction, percutaneous administration, vaginal administration, urethral administration, rectal administration, buccal administration, oral administration, pulmonary administration, ear administration, muscular administration, hypodermic administration, and intravenous administration. 15. The method according to claim 4, between said step (5-1) and step (6), further comprising a step (5-2) of reacting the product of said step (5-1) with one or more selected from lysine, arginine, cystein, thiol alkylamine, polyethyleneimine, polylysine, polyarginine, and protamine. 16. A bioactive molecule delivery composition, containing one or more hydrogels containing the poly(organophosphazene)-bioactive molecule conjugate according to claim 6. 17. The bioactive molecule delivery composition according to claim 16, further comprising one or more selected from the group consisting of additional bioactive molecules, cells and additives. 18. The bioactive molecule delivery composition according to claim 17, wherein the content of the additive is 1.times.10.sup.-6 to 30 wt % based on the total weight of the composition, and the additive is selected from the group consisting of cationic polymers having the molecular weight from 200 to 750,000, poly(N-vinyl-2-pyrrolidone), polyvinylacetate (PVA), hyaluronic acid, chondroitin sulfate, heparin, alginate, amiloride, procainamide, acetyl-beta-methylcholine, spermine, spermidine, lysozyme, fibroin, albumin, collagen, growth factors, bone morphogenetic proteins (BMPs), dexamethason, fibronectin, fibrinogen, thrombin, proteins, cremophor EL, dexrazoxane, leucovorin, ricinoleic acid, phospholipid, small intestinal submucosa, vitamin E, polyglycerol ester of fatty acid, Labrafil, Labrafil M1944CS, citric acid, glutamic acid, hydroxypropyl methylcellulose, gelatin, isopropyl myristate, Eudragit, tego betain, dimyristoylphosphatidylcholine, scleroglucan, ethanol, dimethyl sulfoxide, preservatives, sugars, polyols, sugar-containing polyols, amino acids, polymer-containing polyols, sugar-containing amino acids, surfactants, sugar-containing ions, silicate, NaCl, KCl, NaBr, Nal, LiCl, n-Bu.sub.4NBr, n-Pr.sub.4NBr, Et.sub.4NBr, Mg(OH).sub.2, Ca(OH).sub.2, ZnCO.sub.3, Ca.sub.3(PO.sub.4).sub.2, ZnCl.sub.2, (C.sub.2H3O.sub.2).sub.2Zn, ZnCO.sub.3, CdCl.sub.2, HgCl.sub.2, CoCl.sub.2, (CaNO.sub.3).sub.2, BaCl.sub.2, MgCl.sub.2, PbCl.sub.2, AlCl.sub.3, FeCl.sub.2, FeCl.sub.3, NiCl.sub.2, AgCl, AuCl.sub.3, CuCl.sub.2, sodium tetradecyl sulfate, dodecyltrimethylammonium bromide, dodecyltrmethylammonium chloride, and tetradecyltrimethylammonium bromide. 19. The bioactive molecule delivery composition according to claim 17, wherein the additional bioactive molecule is selected from the group consisting of proteins, polypeptides, peptides, vaccines, genes, hormones, anti-cancer drugs, and angiogenesis inhibitors and the content of the additional bioactive molecule is from 1.times.10.sup.-8 to 50 vol % based on the total volume of the composition. 20. The bioactive molecule delivery composition according to claim 19, wherein the protein, polypeptide, or peptide is one or more selected from the group consisting of erythropoietin (EPO), interferon-alpha, interferon-beta, interferon-gamma, growth hormone, growth hormone releasing factor, nerve growth factor (NGF), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), macrophage-colony stimulating factor (M-CSF), blood clotting factor, insulin, oxytocin, vasopressin, adrenocorticotropic hormone, epidermal growth factor, platelet-derived growth factor (PDGF), prolactin, luliberin, luteinizing hormone releasing hormone (LHRH), LHRH agonists, LHRH antagonists, somatostatin, glucagon, interleukin-2(IL-2), interleukin-11(IL-11), gastrin, tetragastrin, pentagastrin, urogastrone, secretin, calcitonin, enkephalins, endorphins, angiotensins, thyrotropin releasing hormone(TRH), tumor necrosis factor (TNF), tumor necrosis factor related apoptosis inducing ligand (TRAIL), heparinase, bone morphogenic protein (BMP), human atrial natriuretic peptide (hANP), glucagon-like peptide (GLP-1), renin, bradykinin, bacitracins, polymyxins, colistins, tyrocidine, gramicidins, cyclosporins and synthetic analogs thereof, monoclonal antibody, antibody, ferment, and cytokines; the vaccine is hepatitis vaccine; the gene is one or more selected from the group consisting of small interference RNA (siRNA), plasmid DNA, and antisense oligodeoxynucleotide (AS-ODN); the hormone is one or more selected from the group consisting of testosterone, estradiol, progesterone, prostaglandins and synthetic analogs thereof; the anti-cancer drug is one or more selected from the group consisting of paclitaxel, doxorubicin, 5-fluorouracil, cisplatin, carboplatin, oxaliplatin, tegafur, irinotecan, docetaxel, cyclophosphamide, cemcitabine, ifosfamide, mitomycin C, vincristine, etoposide, methotrexate, topotecan, tamoxifen, vinorelbine, camptothecin, danuorubicin, chlorambucil, bryostatin-1, calicheamicin, mayatansine, levamisole, DNA recombinant interferon alfa-2a, mitoxantrone, nimustine, interferon alfa-2a, doxifluridine, formestane, leuprolide acetate, megestrol acetate, carmofur, teniposide, bleomycin, carmustine, heptaplatin, exemestane, anastrozole, estramustine, capecitabine, goserelin acetate, polysaccharide potassium, medroxypogesterone acetate, epirubicin, letrozole, pirarubicin, topotecan, altretamine, toremifene citrate, BCNU, taxotere, actinomycin D, polyethylene glycol conjugated protein, and synthetic analogs thereof; and the angiogenesis inhibitor is one or more selected from the group consisting of BMS-275291, Clodronate, 6-deoxy-6-demethyl-4-dedimethylaminotetracycline, Doxycycline, Marimastat, 2-Methoxyestradiol, Squalamine, SU5164, Thalidomide, TNP-470, Combretastatin A4, Soy Isoflavone, Enzastaurin, CC 5013, Celecoxib, ZD 6474, Halofuginone hydrobromide, interferon-alpha, Bevacizumab, AE-941, Interleukin-12, VEFG-trap, Cetuximab, and synthetic analogs thereof. 21. The bioactive molecule delivery composition according to claim 17, wherein the cell is one or more selected from the group consisting of preosteoblast, chondrocyte, umbilical vein endothelial cell (UVEC), osteoblast, adult stem cell, schwann cell, oligodendrocyte, hepatocyte, mural cell (used in combination with UVEC), myoblast, insulin-secreting cell, endothelial cell, smooth muscle cell, fibroblast, .beta.-cell, endodermal cell, hepatic stem cell, juxraglomerular cell, skeletal muscle cell, keratinocyte, melanocyte, langerhans cell, merkel cell, dermal fibroblast, and preadipocyte. 22. The bioactive molecule delivery composition according to claim 16, which is administered through an administration route selected from the group consisting of administration to outward intestinal tract, opthalmologically administration, injection into the cartilage tissue, bone tissue, fat tissue or cancer tissue, suction, percutaneous administration, vaginal administration, urethral administration, rectal administration, buccal administration, oral administration, pulmonary administration, ear administration, muscular administration, hypodermic administration, and intravenous administration.

Details for Patent 8,287,888

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2026-04-04
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2026-04-04
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007		2026-04-04
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2026-04-04